BACKGROUND: Our objectives were to describe the frequency and determine risk factors for hearing deterioration following pediatric stem cell transplantation (SCT). METHODS: In this prospective cohort study, we performed pure tone audiometry and measured otoacoustic emissions (OAE) prior to and following SCT. Worse hearing was considered deterioration in either audiometry or OAE. RESULTS: Between October 2000 and November 2002, 45 informative audiometry or OAE results were obtained. Hearing deteriorated following SCT in 20/45 (44%) of these children. Those with worse hearing following SCT were more likely to have neuroblastoma (odds ratio [OR] 16.0 [95% CI 1.8, 143.2; P = 0.003]), receive carboplatin conditioning (OR 7.7 [95% CI 1.4, 41.9; P = 0.01]), have abnormal baseline hearing (OR 5.1 [95% CI 1.3, 19.5; P = 0.02]), and have higher baseline serum creatinine (OR for every increase of 5 micromol/L of serum creatinine of 1.5 [95% CI 1.03, 2.1; P = 0.03]). CONCLUSION: Many children who undergo SCT will have deterioration in hearing following SCT. A high-risk group of children can be delineated who may benefit from more intensive audiological monitoring following SCT. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND: Our objectives were to describe the frequency and determine risk factors for hearing deterioration following pediatric stem cell transplantation (SCT). METHODS: In this prospective cohort study, we performed pure tone audiometry and measured otoacoustic emissions (OAE) prior to and following SCT. Worse hearing was considered deterioration in either audiometry or OAE. RESULTS: Between October 2000 and November 2002, 45 informative audiometry or OAE results were obtained. Hearing deteriorated following SCT in 20/45 (44%) of these children. Those with worse hearing following SCT were more likely to have neuroblastoma (odds ratio [OR] 16.0 [95% CI 1.8, 143.2; P = 0.003]), receive carboplatin conditioning (OR 7.7 [95% CI 1.4, 41.9; P = 0.01]), have abnormal baseline hearing (OR 5.1 [95% CI 1.3, 19.5; P = 0.02]), and have higher baseline serum creatinine (OR for every increase of 5 micromol/L of serum creatinine of 1.5 [95% CI 1.03, 2.1; P = 0.03]). CONCLUSION: Many children who undergo SCT will have deterioration in hearing following SCT. A high-risk group of children can be delineated who may benefit from more intensive audiological monitoring following SCT. Copyright 2004 Wiley-Liss, Inc.
Authors: Wendy Landier; Kristin Knight; F Lennie Wong; Jin Lee; Ola Thomas; Heeyoung Kim; Susan G Kreissman; Mary Lou Schmidt; Lu Chen; Wendy B London; James G Gurney; Smita Bhatia Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Kristin R Knight; Lu Chen; David Freyer; Richard Aplenc; Mary Bancroft; Bonnie Bliss; Ha Dang; Biljana Gillmeister; Eleanor Hendershot; Dale F Kraemer; Lanie Lindenfeld; Jane Meza; Edward A Neuwelt; Brad H Pollock; Lillian Sung Journal: J Clin Oncol Date: 2016-12-12 Impact factor: 44.544
Authors: Daniel B Hawcutt; Munir Pirmohamed; Signe Thiesen; Peng Yin; Andrea L Jorgensen; Jieying Eunice Zhang; Valentina Manzo; Laurence McEvoy; Christopher Barton; Susan Picton; Simon Bailey; Penelope Brock; Harish Vyas; David Walker; Guy Makin; Srinivas Bandi; Barry Pizer Journal: Pharmacogenet Genomics Date: 2017-06 Impact factor: 2.089
Authors: Eva Clemens; Marry M van den Heuvel-Eibrink; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Roderick Skinner; Louis S Constine; Johnnie K Bass; Claudia E Kuehni; Thorsten Langer; Elvira C van Dalen; Edith Bardi; Nicolas-Xavier Bonne; Penelope R Brock; Beth Brooks; Bruce Carleton; Eric Caron; Kay W Chang; Karen Johnston; Kristin Knight; Paul C Nathan; Etan Orgel; Pinki K Prasad; Jan Rottenberg; Katrin Scheinemann; Andrica C H de Vries; Thomas Walwyn; Annette Weiss; Antoinette Am Zehnhoff-Dinnesen; Richard J Cohn; Wendy Landier Journal: Lancet Oncol Date: 2019-01 Impact factor: 54.433
Authors: Sally Cohen-Cutler; Kenneth Wong; Victoria Mena; Kevin Sianto; Michael A Wright; Arthur Olch; Etan Orgel Journal: Int J Radiat Oncol Biol Phys Date: 2021-03-04 Impact factor: 8.013